GENMAB: Stærke data for Tisotumumab i livmoderhalskræft
84873 Helge Larsen/PI-redaktør 30/6 2020 05:20
Genmab Announces Very Favorable Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer.
https://ir.genmab.com/news-releases/news-release-details/genmab-announces-very-favorable-topline-results-phase-2-clinical
https://ir.genmab.com/news-releases/news-release-details/genmab-announces-very-favorable-topline-results-phase-2-clinical